Sandbox 45673

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 16: Line 16:
==Mechanism==
==Mechanism==
Finasteride is a 5-alpha reductase inhibitor. There are two isoforms of the 5alpha-reductase enzyme, type I and II, and while the drug has a higher affinity for the type II enzyme, it also inhibits the function of the type I. (Schieck,1998.)
Finasteride is a 5-alpha reductase inhibitor. There are two isoforms of the 5alpha-reductase enzyme, type I and II, and while the drug has a higher affinity for the type II enzyme, it also inhibits the function of the type I. (Schieck,1998.)
-
Typically 5 alpha-redcutase turns testosterone into Dihydrotestosterone(DHT), but the enzyme will accept Finasteride as an alternate substrate; turning it into dihydrofinasteride through an enzyme bound, NADP-dihydrofinasteride adduct. Finasteride is similar in structure to testosterone and 5alpha-reductase has almost the same affinity for both molecules. However, Finasteride , having a high affinity for 5 alpha-reductase, covalently binds to the enzyme as a Michael acceptor, through a functionally irreversible reaction. However, the NADP-dihydrofinasteride complex breaks down with a half life of about 1 month at 37˚C., which is why patients must continue taking the drug.(Bull ''et. al,1995'')
+
Typically -redcutase turns testosterone into Dihydrotestosterone(DHT), but the enzyme will accept Finasteride as an alternate substrate; turning it into dihydrofinasteride through an enzyme bound, NADP-dihydrofinasteride adduct. Finasteride is similar in structure to testosterone and 5alpha-reductase has almost the same affinity for both molecules. However, Finasteride , having a high affinity for -reductase, covalently binds to the enzyme as a Michael acceptor, through a functionally irreversible reaction. However, the NADP-dihydrofinasteride complex breaks down with a half life of about 1 month at 37˚C., which is why patients must continue taking the drug.(Bull ''et. al,1995'')
==Medical==
==Medical==
-
Finasteride is used to shrink an enlarged prostate, also known as benign prostatic hyperplasia (BPH), in adult men (Allen, 2015). Enlarged prostate is located near the bladder which causes difficulty with passing urine. Common symptoms include, long period of time before urine flow, feeling the bladder is not empty, and dribbling urine (Allen, 2015). This medication works by blocking the enzyme 5a-reductase, which prevents conversion of testosterone to the natural body hormone, [[dihydrosestosterone]] (DHT) that causes growth of the prostate. As a result, reducing the amount of dihydrotestosterone causes the prostate to shrink. Thus, helps the urine pass easily. *I plan to add hyperlinks*
+
Finasteride is used to shrink an enlarged prostate, also known as benign prostatic hyperplasia (BPH), in adult men (Allen, 2015). Enlarged prostate is located near the bladder which causes difficulty with passing urine. Common symptoms include, long period of time before urine flow, feeling the bladder is not empty, and dribbling urine (Allen, 2015). This medication works by blocking the enzyme -reductase, which prevents conversion of testosterone to the natural body hormone, dihydrosestosterone (DHT) that causes growth of the prostate. As a result, reducing the amount of dihydrotestosterone causes the prostate to shrink. Thus, helps the urine pass easily. *I plan to add hyperlinks*
Finasteride can also lead to improvements in Androgenetic alopecia, male pattern baldness (MPB), which is caused by an androgen-dependent miniaturization of scalp hair follicles. Testosterone is the major flow of androgen, but to be maximally active in scalp hair follicles it must be converted to dihydrotestosterone (DHT) by the enzyme 5a- reductase. DHT is an important factor in MPB by the absence of the condition in males with a insufficiency of type II 5a-reductase, and by small amounts of hair regrowth in men with MPB (Olsen, et al., 2006). Finasteride acts as an inhibitor for the type II 5a-reductase enzyme, which has shown to reduce both serum and scalp skin dihydrotestosterone levels in balding men (Leyden, et al., 1999). Side effects from Finasteride include but are not limited to, decreased sexual ability and desire.
Finasteride can also lead to improvements in Androgenetic alopecia, male pattern baldness (MPB), which is caused by an androgen-dependent miniaturization of scalp hair follicles. Testosterone is the major flow of androgen, but to be maximally active in scalp hair follicles it must be converted to dihydrotestosterone (DHT) by the enzyme 5a- reductase. DHT is an important factor in MPB by the absence of the condition in males with a insufficiency of type II 5a-reductase, and by small amounts of hair regrowth in men with MPB (Olsen, et al., 2006). Finasteride acts as an inhibitor for the type II 5a-reductase enzyme, which has shown to reduce both serum and scalp skin dihydrotestosterone levels in balding men (Leyden, et al., 1999). Side effects from Finasteride include but are not limited to, decreased sexual ability and desire.

Revision as of 22:48, 5 December 2016

N-(1,1-dimethylethyl)-3-oxo-(5α,17β)-4-azaandrost-1-ene-17-carboxamide

N-(1,1-dimethylethyl)-3-oxo- (5α,17β)-4-azaandrost-1-ene-17-carboxamide bound to 5α-reductase (PDB code 3g1r)

Drag the structure with the mouse to rotate

References

  1. 1.0 1.1 I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 121, 246. ISBN 978-94-011-4439-1

Allen, Helen. (2015, March). "Finasteride for prostate gland enlargement. Information. Patient.

Bull, Herbert G.*Garcia-Calvo,Margarita Andersson,Stefan†, Baginsky, Walter F.,Chan,H. Karen,Ellsworth,‡ Dina E., Miller,§ Randall R., Stearns,Ralph A.,Bakshi,Raman K.,Rasmusson, Gary H.,Tolman,Richard L., Myers,Robert W.,Kozarich,John W.,Harris,Georgianna S. (1995, August 6) Mechanism-Based Inhibition of Human Steroid 5R-Reductase by Finasteride: Enzyme-Catalyzed Formation of NADP-Dihydrofinasteride, a Potent Bisubstrate Analog Inhibitor. http://pubs.acs.org/doi/pdf/10.1021/ja953069t

Leyden, J., Dunlap, F., & Miller, B., et el. (1999, June). Finasteride in the treatment of men with frontal male pattern hair loss.

Olsen, E. A., Hordinsky, M., & Whiting, D., et al. (2006, December). The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: Results of a randomized placebo-controlled study of dutasteride versus finasteride.

Schieck, Cynthia L.(1998, August) "Finasteride (Propecia ®)". http://www.chm.bris.ac.uk/motm/finasteride/Finasteride%20(Propecia)%20-%20Feature%20Molecule.htm

Personal tools